BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 19271376)

  • 41. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours.
    Jacot W; Bessis D; Jorda E; Ychou M; Fabbro M; Pujol JL; Guillot B
    Br J Dermatol; 2004 Jul; 151(1):238-41. PubMed ID: 15270903
    [No Abstract]   [Full Text] [Related]  

  • 42. Ecthymatous skin eruption during therapy with cetuximab.
    Navarini AA; Kamacharova I; Kerl K; Donghi D; Cozzio A
    Eur J Dermatol; 2011; 21(2):282-3. PubMed ID: 21489913
    [No Abstract]   [Full Text] [Related]  

  • 43. [Skin eruptions as an adverse reaction to epidermal growth-factor receptor inhibitors].
    Tjin-A-ton ML; van Montfrans C; Koldenhof JJ; Sigurdsson V; Voest EE; Witteveen PO
    Ned Tijdschr Geneeskd; 2007 Apr; 151(17):945-52. PubMed ID: 17520845
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Cutaneous toxicity associated with cetuximab treatment in metastatic colorectal cancer].
    Rodríguez-Murphy E; Villanueva-Herraiz S; Ortega-García MP; Pérez-Feliu A; López-Montenegro Soria MA; Camps-Herrero C
    Farm Hosp; 2011; 35(3):114-20. PubMed ID: 21497124
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A double-blind, placebo-controlled study of the safety and efficacy of vitamin K1 ointment for the treatment of patients with cetuximab-induced acneiform eruption.
    Hashimoto H; Iwasa S; Yanai T; Honma Y; Kato K; Hamaguchi T; Yamada Y; Shimada Y; Namikawa K; Tsutsumida A; Yamazaki N; Yamamoto H
    Jpn J Clin Oncol; 2013 Jan; 43(1):92-4. PubMed ID: 23136238
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events.
    Lenz HJ
    Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):5-13. PubMed ID: 16736978
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Cutaneous side effects of EGF receptor inhibitors].
    Nassar D; Soutou B; Aractingi S
    Bull Cancer; 2009 Dec; 96 Suppl():S85-91. PubMed ID: 20034874
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Acneiform eruption secondary to cetuximab with pseudomalignant histopathological changes].
    Vidal-Olmo I; Bassas-Vila J; Herrera-Acosta E; Umbert-Millet P
    Actas Dermosifiliogr; 2008 Mar; 99(2):159-60. PubMed ID: 18346444
    [No Abstract]   [Full Text] [Related]  

  • 49. Atypical folliculitis caused by Malassezia spp. in immunosuppressed patients.
    Marín-Hernández E; Mejía-Mancera CG; Quijada-Henderson MA; Valero-Gómez A
    Bol Med Hosp Infant Mex; 2022; 79(1):62-68. PubMed ID: 35086132
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Acneiform eruption following molecular targeted chemotherapy.
    Vaccaro M; Barbuzza O; Pollicino A; Guarneri C
    Intern Med J; 2011 Apr; 41(4):361-2. PubMed ID: 21507168
    [No Abstract]   [Full Text] [Related]  

  • 51. [EGFR (epidermal growth factor receptor) inhibitor-associated skin disorders in tumor therapy].
    Reimer G; Brudler O; Heinrich B; Bangerter M
    MMW Fortschr Med; 2008 Dec; 150(49-50):37-8, 40. PubMed ID: 19133368
    [No Abstract]   [Full Text] [Related]  

  • 52. [Cutaneous side effects of EGF-receptor inhibition and their management].
    Gutzmer R; Werfel T; Kapp A; Elsner J
    Hautarzt; 2006 Jun; 57(6):509-13. PubMed ID: 16205868
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Severe acneiform rash.
    Yamamoto DS; Viale PH; Zhao G
    Clin J Oncol Nurs; 2004 Dec; 8(6):654-6. PubMed ID: 15637959
    [No Abstract]   [Full Text] [Related]  

  • 54. [Malassezia folliculitis in an immunocompromised patient].
    Mota R; Reifenberger J; Homey B; Bruch-Gerharz D
    Hautarzt; 2011 Oct; 62(10):725-7. PubMed ID: 21915732
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical characteristics and treatment outcomes of Pityrosporum folliculitis in immunocompetent patients.
    Green M; Feschuk AM; Kashetsky N; Maibach HI
    Arch Dermatol Res; 2023 Aug; 315(6):1497-1509. PubMed ID: 36517586
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Duration of Oral Antibiotics Administration for Cetuximab-Induced Acneiform Eruption.
    Park JH; Choi Y; Kim HJ; Oh SJ; Lee DY; Lee JH; Lee JH
    Dermatology; 2021; 237(3):457-463. PubMed ID: 33302268
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption.
    Scope A; Lieb JA; Dusza SW; Phelan DL; Myskowski PL; Saltz L; Halpern AC
    J Am Acad Dermatol; 2009 Oct; 61(4):614-20. PubMed ID: 19646778
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Follicular drug eruption induced by gefitinib (ZD 1839, iressa): clinical picture correlates with in vitro data of focal epidermal necrosis after epidermal growth factor inhibition in skin cultures.
    Treudler R; Zouboulis CC
    Dermatology; 2005; 211(4):375-6. PubMed ID: 16286753
    [No Abstract]   [Full Text] [Related]  

  • 59. Aripiprazole-induced acneiform eruption.
    Mishra B; Praharaj SK; Prakash R; Sinha VK
    Gen Hosp Psychiatry; 2008; 30(5):479-81. PubMed ID: 18774434
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Cetuximab monotherapy in advanced cervical cancer: a retrospective study with five patients.
    Hertlein L; Lenhard M; Kirschenhofer A; Kahlert S; Mayr D; Burges A; Friese K
    Arch Gynecol Obstet; 2011 Jan; 283(1):109-13. PubMed ID: 20180130
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.